Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Update

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 4,340,000 shares, an increase of 5.6% from the October 15th total of 4,110,000 shares. Based on an average daily volume of 524,700 shares, the days-to-cover ratio is currently 8.3 days. Approximately 7.9% of the shares of the stock are sold short.

Insider Activity at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Caxton Associates LP boosted its position in shares of Agios Pharmaceuticals by 0.7% during the second quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock worth $1,615,000 after buying an additional 264 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares during the period. CANADA LIFE ASSURANCE Co boosted its holdings in Agios Pharmaceuticals by 1.8% in the first quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock valued at $911,000 after purchasing an additional 540 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Agios Pharmaceuticals by 6.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock valued at $539,000 after purchasing an additional 688 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in Agios Pharmaceuticals in the second quarter valued at $37,000.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Scotiabank increased their price objective on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a research report on Friday, November 1st. Raymond James reiterated an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $52.33.

Agios Pharmaceuticals Stock Down 1.7 %

AGIO opened at $52.89 on Tuesday. Agios Pharmaceuticals has a 52 week low of $20.96 and a 52 week high of $62.58. The business has a fifty day simple moving average of $46.62 and a 200-day simple moving average of $44.07. The firm has a market cap of $3.02 billion, a P/E ratio of 4.66 and a beta of 0.75.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.